Document Detail

The kinetic profile of vancomycin in neonates.
MedLine Citation:
PMID:  9877311     Owner:  NLM     Status:  MEDLINE    
The pharmacokinetic parameters of vancomycin in a neonatal population have been characterized to enable development of optimum dosage guidelines for neonatal intensive-care units and to examine the relationship between these pharmacokinetic parameters and various demographic, developmental and clinical factors which might be associated with changes in the kinetic profile of vancomycin. Forty-four infants (twenty-five males and nineteen females) with suspected or proven Gram-positive infection and who received intravenous vancomycin between October 1993 and December 1996 were included in this retrospective analysis. Gestational age ranged from 25 to 40 weeks and postconceptional age at the time of the study ranged from 28 to 45 weeks. Sixty case-studies were obtained from the forty-four patients, with one period of study corresponding to one week or one cycle of therapy. Vancomycin pharmacokinetic parameters were determined by use of a one-compartment model. By regression analysis the current weight (g) was shown to be the stronger covariate, and both vancomycin clearance (L h(-1)) and volume of distribution (L) had to be normalized. The vancomycin volume of distribution depended on the postconceptional age with a cut-off at 32 weeks, whereas vancomycin clearance depended on the presence or absence of concomitant treatment with indomethacin or of mechanical ventilation, or both. On the basis of the pharmacokinetic parameters obtained we suggest initial dosage guidelines for vancomycin ranging from 10 mg kg(-1) every 8 h to 10 mg kg(-1) every 12 h, depending on the demographic and clinical characteristics of the patients. The results obtained enabled application of better a priori and a posteriori dosage schedules to infants in neonatal intensive-care units by use of the Bayesian approach, although further prospective study is recommended before direct extrapolation to patients in other settings.
R Silva; E Reis; M A Bispo; A M Almeida; I M Costa; F Falcão; J M Palminha; A C Falcão
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of pharmacy and pharmacology     Volume:  50     ISSN:  0022-3573     ISO Abbreviation:  J. Pharm. Pharmacol.     Publication Date:  1998 Nov 
Date Detail:
Created Date:  1999-04-26     Completed Date:  1999-04-26     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0376363     Medline TA:  J Pharm Pharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1255-60     Citation Subset:  IM    
Pharmacy Department, São Francisco Xavier Hospital, Lisboa, Portugal.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Body Weight
Drug Interactions
Gram-Positive Bacterial Infections / drug therapy*
Guidelines as Topic
Indomethacin / pharmacology
Infant, Newborn / metabolism*
Injections, Intravenous
Intensive Care / standards
Metabolic Clearance Rate / physiology*
Regression Analysis
Retrospective Studies
Tissue Distribution
Vancomycin / pharmacokinetics*
Reg. No./Substance:
1404-90-6/Vancomycin; 53-86-1/Indomethacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacokinetics and hypotensive effect of diltiazem in rabbits: comparison of diltiazem with its ma...
Next Document:  6-Mercaptopurine pharmacokinetics after use of azathioprine in renal transplant recipients with inte...